Drug Trial Radar · NCT04168385
MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study
Last checked: Nov 20, 2026Latest source record: Dec 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
52
Actual
Start
Jan 16, 2020
Primary completion
Sep 4, 2024
Study completion Sep 4, 2024
Sponsor
- Lead sponsor
- Mirum Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 19, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluate the long-term safety of maralixibat (MRX) in subjects with cholestatic liver disease including, but not limited to, Alagille Syndrome (ALGS), Progressive Familial Intrahepatic Cholestasis (PFIC) and Biliary Atresia.
Conditions
- Cholestatic Liver Disease
Interventions
MaralixibatDrug
Maralixibat chloride oral solution orally twice daily (up to 1200\* mcg/kg/day), and according to indication. \*equivalent to 1140 mcg/kg/day maralixibat
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse EventsTime frame: From informed consent through approximately 4.5 years, including 30 days after last dose.
Locations
17 sites in 8 countries. Site status is shown where the registry gives one.
Children'S Hospital Los Angeles
Los Angeles, California
Riley Hospital For Children
Indianapolis, Indiana
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Children Hospital of Pittsburgh
Pittsburgh, Pennsylvania
Baylor College of Medicine/Texas Children's Hospital
Houston, Texas
Seattle Children's Hospital
Seattle, Washington
Children's Hospital Westmead
Westmead, New South Wales, Australia
The Royal Children'S Hospital Melbourne
Parkville, Victoria, Australia
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Hospital for Sick Children
Toronto, Canada
Hopital Necker-Enfants Malades
Paris, France
Hopital Kremlin Bicetre
Paris, France
The Children's Memorial Health Institute
Warsaw, Poland
Hospital Universitario La Paz- Hospital Materno Infantil
Madrid, Spain
Birmingham Children's Hospital
Birmingham, United Kingdom
Leeds Teaching Hospital NHS Trust
Leeds, United Kingdom
Paediatric Liver Center, Kings College Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.